Summary of opinion: Zynyz, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Zynyz, 29/01/2026 Positive
Summary of opinion: Efmody, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Efmody, 29/01/2026 Positive
Summary of opinion: Akeega, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Akeega, 29/01/2026 Positive
EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Summary of opinion: Imfinzi, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Imfinzi, 29/01/2026 Positive
Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Date of authorisation: 21/11/2014, Revision: 21, Status: Authorised
Submitted by Anonymous (not verified) on 30 January 2026 - 10:52
Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Date of authorisation: 21/11/2014, Revision: 21, Status: Authorised
First immunotherapy-based treatment recommended for advanced anal cancer
Submitted by Anonymous (not verified) on 30 January 2026 - 10:50
First immunotherapy-based treatment recommended for advanced anal cancer
List of centrally authorised products with safety-related changes to the product information
Submitted by Anonymous (not verified) on 30 January 2026 - 10:00
List of centrally authorised products with safety-related changes to the product information
Human medicines European public assessment report (EPAR): Qdenga, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 05/12/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 30 January 2026 - 9:42
Human medicines European public assessment report (EPAR): Qdenga, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 05/12/2022, Revision: 6, Status: Authorised